Weiss Ratings Reaffirms Hold (C) Rating for Niagen Bioscience (NASDAQ:NAGE)

Niagen Bioscience (NASDAQ:NAGE - Get Free Report)'s stock had its "hold (c)" rating reissued by equities research analysts at Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.

Several other equities analysts have also recently issued reports on the company. HC Wainwright boosted their target price on Niagen Bioscience from $11.00 to $12.00 and gave the company a "buy" rating in a research note on Monday, August 11th. Wall Street Zen cut Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, September 9th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $13.42.

Niagen Bioscience Stock Up 2.0%

NASDAQ NAGE opened at $7.57 on Friday. The stock's 50-day simple moving average is $8.90 and its two-hundred day simple moving average is $9.64. Niagen Bioscience has a twelve month low of $3.45 and a twelve month high of $14.69. The company has a market capitalization of $603.71 million, a price-to-earnings ratio of 36.05 and a beta of 2.13.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. Niagen Bioscience had a return on equity of 23.12% and a net margin of 15.24%.The business had revenue of $31.12 million for the quarter, compared to the consensus estimate of $28.55 million.

Institutional Investors Weigh In On Niagen Bioscience

A number of hedge funds have recently added to or reduced their stakes in the stock. Precision Wealth Strategies LLC purchased a new stake in Niagen Bioscience during the 3rd quarter valued at $1,527,000. Silverberg Bernstein Capital Management LLC bought a new stake in shares of Niagen Bioscience during the 3rd quarter valued at $1,169,000. BSW Wealth Partners bought a new stake in shares of Niagen Bioscience during the 3rd quarter valued at $793,000. CoreCap Advisors LLC bought a new stake in shares of Niagen Bioscience during the 3rd quarter valued at $544,000. Finally, SG Americas Securities LLC bought a new stake in shares of Niagen Bioscience during the 3rd quarter valued at $482,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.